Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 15783 | 623 | 41.7 | 92% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | APELIN | Author keyword | 462 | 78% | 49% | 304 |
| 2 | APJ | Author keyword | 301 | 96% | 15% | 94 |
| 3 | APELIN 13 | Author keyword | 90 | 96% | 4% | 27 |
| 4 | APJ RECEPTOR | Author keyword | 65 | 93% | 4% | 25 |
| 5 | APELIN RECEPTOR | Author keyword | 38 | 86% | 3% | 19 |
| 6 | LEARNING PHARMACOPROTE | Address | 18 | 89% | 1% | 8 |
| 7 | APELIN 12 | Author keyword | 15 | 88% | 1% | 7 |
| 8 | APELIN APJ | Author keyword | 4 | 67% | 1% | 4 |
| 9 | APELINERGIC SYSTEM | Author keyword | 3 | 100% | 0% | 3 |
| 10 | RECEPTOR APJ | Author keyword | 3 | 100% | 0% | 3 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | APELIN | 462 | 78% | 49% | 304 | Search APELIN | Search APELIN |
| 2 | APJ | 301 | 96% | 15% | 94 | Search APJ | Search APJ |
| 3 | APELIN 13 | 90 | 96% | 4% | 27 | Search APELIN+13 | Search APELIN+13 |
| 4 | APJ RECEPTOR | 65 | 93% | 4% | 25 | Search APJ+RECEPTOR | Search APJ+RECEPTOR |
| 5 | APELIN RECEPTOR | 38 | 86% | 3% | 19 | Search APELIN+RECEPTOR | Search APELIN+RECEPTOR |
| 6 | APELIN 12 | 15 | 88% | 1% | 7 | Search APELIN+12 | Search APELIN+12 |
| 7 | APELIN APJ | 4 | 67% | 1% | 4 | Search APELIN+APJ | Search APELIN+APJ |
| 8 | APELINERGIC SYSTEM | 3 | 100% | 0% | 3 | Search APELINERGIC+SYSTEM | Search APELINERGIC+SYSTEM |
| 9 | RECEPTOR APJ | 3 | 100% | 0% | 3 | Search RECEPTOR+APJ | Search RECEPTOR+APJ |
| 10 | APELIN 36 | 3 | 60% | 0% | 3 | Search APELIN+36 | Search APELIN+36 |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | APJ RECEPTOR | 297 | 87% | 23% | 146 |
| 2 | ENDOGENOUS LIGAND APELIN | 296 | 93% | 18% | 110 |
| 3 | ORPHAN RECEPTOR APJ | 289 | 95% | 15% | 96 |
| 4 | HUMAN APJ RECEPTOR | 215 | 92% | 14% | 87 |
| 5 | PEPTIDE APELIN | 202 | 92% | 13% | 80 |
| 6 | ENDOGENOUS PEPTIDE LIGAND | 197 | 97% | 9% | 58 |
| 7 | APJ | 79 | 82% | 7% | 46 |
| 8 | ENDOGENOUS INOTROPE APELIN | 76 | 100% | 4% | 24 |
| 9 | CENTRALLY ADMINISTERED APELIN 13 | 41 | 100% | 2% | 15 |
| 10 | LIGAND APELIN | 41 | 100% | 2% | 15 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Apelin, diabetes, and obesity | 2011 | 54 | 76 | 86% |
| The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis | 2013 | 27 | 184 | 85% |
| The protective effect of apelin on ischemia/reperfusion injury | 2015 | 1 | 35 | 83% |
| Apelin, a promising target for type 2 diabetes treatment? | 2012 | 30 | 50 | 82% |
| Translational promise of the apeline-APJ system | 2010 | 45 | 52 | 98% |
| Apelin and its receptor APJ in cardiovascular diseases | 2014 | 5 | 91 | 93% |
| Biology of the apelin-APJ axis in vascular formation | 2012 | 20 | 60 | 87% |
| International Union of Basic and Clinical Pharmacology. LXXIV. Apelin Receptor Nomenclature, Distribution, Pharmacology, and Function | 2010 | 39 | 141 | 94% |
| The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR | 2014 | 4 | 76 | 84% |
| The role of apelin in cardiovascular function and heart failure | 2008 | 65 | 69 | 93% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | LEARNING PHARMACOPROTE | 18 | 89% | 1.3% | 8 |
| 2 | U691 | 3 | 33% | 1.3% | 8 |
| 3 | CENT NEUROPEPTIDES REGULAT BODY FLUID HOMEOST | 3 | 60% | 0.5% | 3 |
| 4 | SERV BIOCHEM MOL GENET | 1 | 38% | 0.5% | 3 |
| 5 | U 589 | 1 | 50% | 0.3% | 2 |
| 6 | UNITE ENVIRONM PERINATAL CROISSANCEEA 4489 | 1 | 100% | 0.3% | 2 |
| 7 | UNITE INSERM U397 | 1 | 100% | 0.3% | 2 |
| 8 | UNITE U589 | 1 | 100% | 0.3% | 2 |
| 9 | ESH EXCELLENT HYPERTENS | 1 | 40% | 0.3% | 2 |
| 10 | SCOTTISH ADV HEART FAILURE UNIT | 1 | 40% | 0.3% | 2 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000099720 | VISFATIN//NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE//NAMPT |
| 2 | 0.0000099596 | CHEMERIN//VASPIN//OMENTIN |
| 3 | 0.0000068213 | SALUSIN//SALUSIN BETA//SALUSIN ALPHA |
| 4 | 0.0000055879 | NESFATIN 1//NUCB2//NUCLEOBINDIN 2 |
| 5 | 0.0000045895 | ANGIOTENSIN 1 7//ANGIOTENSIN CONVERTING ENZYME 2//MAS RECEPTOR |
| 6 | 0.0000037332 | BIOCHEM STEM CELL//BIOL MOL NUTR BIOTECNOL//GRP ENERGY METAB |
| 7 | 0.0000032102 | SPECIALIZED HYPERTENS GENET//HYPERTENS GENET SPECIALIZED//BIOMED IL 236 |
| 8 | 0.0000031708 | IRISIN//FNDC5//ADROPIN |
| 9 | 0.0000030666 | RESISTIN//RESISTIN LIKE MOLECULE BETA//RELM ALPHA |
| 10 | 0.0000026009 | PHARMACOPERONE//MOL PHARMACOL GRP//BRET |